— Know what they know.
Not Investment Advice

SYRE NASDAQ

Spyre Therapeutics, Inc.
1W: -1.8% 1M: +1.8% 3M: +72.0% YTD: +143.0% 1Y: +382.6% 3Y: +1892.5% 5Y: -60.7%
$74.05
-0.27 (-0.36%)
 
Weekly Expected Move ±7.0%
$64 $70 $75 $80 $85
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 55 · $4.5B mcap · 53M float · 2.10% daily turnover · Short 64% of daily vol

Balance Sheet Trends

Total Assets
$778M +27.8% ▲
5Y CAGR: +36.9%
Total Liabilities
$63M -31.0% ▼
5Y CAGR: +23.5%
Shareholders Equity
$715M +38.1% ▲
5Y CAGR: +38.6%
Cash & Investments
$757M +25.4% ▲
5Y CAGR: +38.9%
Total Debt
$0 +0.0% ▲
Net Debt
-$86M +4.1% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$15M$35M$189M$89M$86M
Short-Term Investments$78M$21M$150M$514M$671M
Cash & ST Investments$93M$56M$339M$603M$757M
Net Receivables$815K$375K$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$6M$2M$5M$21M
Total Current Assets$99M$62M$342M$608M$778M
Property, Plant & Equip.$8M$7M$0$0$0
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$3M$2M$331K$10K$0
Total Non-Current Assets$11M$9M$331K$10K$0
Total Assets$110M$71M$342M$608M$778M
— Liabilities —
Accounts Payable$3M$677K$896K$666K$9M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$2M$517K$0$0$0
Other Current Liabilities$5M$5M$6M$53M$50M
Total Current Liabilities$20M$15M$32M$54M$59M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$126M$37M$4M
Total Non-Current Liabilities$6M$6M$126M$37M$4M
Total Liabilities$26M$21M$158M$91M$63M
— Equity —
Common Stock$5K$6K$10K$13K$15K
Retained Earnings-$342M-$426M-$764M-$972M-$1.1B
Accumulated OCI-$20K-$48K$302K$180K$869K
Total Stockholders Equity$84M$50M$184M$518M$715M
Total Liabilities & Equity$110M$71M$342M$608M$778M
— Key Metrics —
Total Debt$5M$5M$0$0$0
Net Debt-$10M-$30M-$189M-$89M-$86M
Total Investments$78M$21M$150M$514M$671M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms